Related by context. All words. (Click for frequent words.) 61 generation purine nucleoside 60 PN# [001] 59 AT# [001] 58 GV# [001] 58 XL# [003] 58 liposomal formulation 58 TRX# 58 volociximab 57 CG# [001] 57 Plicera 57 LX# [003] 56 EP# [003] 56 RP# [002] 56 PEG SN# 56 PRO# [003] 56 RH1 56 DG# [001] 55 vidofludimus 55 DB# [003] 55 orally bioavailable 55 TH# [003] 55 Panzem R NCD 54 NP# [002] 54 NXL# 54 favorable pharmacokinetic profile 54 VP# [003] 54 R#/MEM # 54 PRT# 54 Panzem R 54 nitric oxide donating prostaglandin 54 OXi# 54 PSMA ADC 54 metaglidasen 54 subcutaneously administered 53 ENMD # 53 oral prodrug 53 MEK inhibitor 53 angiogenesis inhibitor 53 EndoTAG TM -1 53 TMC# [002] 53 vascular disrupting agent 53 XL# XL# XL# 53 docetaxel Taxotere R 53 mTOR inhibitor 53 R#/MEM 53 small molecule glucokinase 53 HGS# 53 tumor xenograft models 53 kinase inhibitor 53 NGX# 53 CG# [003] 53 pan HDAC inhibitor 53 EZN 53 TRC# 53 Tasimelteon 53 RhuDex ® 53 HuMax EGFr 53 Protelos 53 ZX# [001] 53 LX# LX# 53 somatostatin analogue 53 evaluating tivozanib 53 ularitide 52 Cloretazine R VNP#M 52 ARX# [001] 52 Octreotide 52 gemcitabine Gemzar ® 52 MB# [004] 52 investigational monoclonal antibody 52 Apoptone 52 ND# [002] 52 Voreloxin 52 erlotinib Tarceva ® 52 signal transduction inhibitor 52 Blinatumomab 52 tyrosine kinase inhibitor 52 subcutaneous formulation 52 DG# [003] 52 Phase Ib study 52 sapacitabine 52 ICA # 52 Amigal 52 Azedra TM 52 EP# [005] 52 Pemetrexed 52 Protelos R 52 V#i [001] 52 #ME# 52 selectively binds 52 TAT# 52 Aurora kinase 52 Androxal TM 52 Sym# 52 DAVANAT 52 connectorized 52 MGCD# [001] 52 TRIOLEX 52 Glufosfamide 52 PD# [005] 52 rHuPH# 52 HGS ETR2 52 Dasatinib 52 Preclinical studies 52 Archexin 52 DXL# 52 CYC# 52 AS# amonafide L malate 52 TG# [001] 52 dopamine partial agonist 52 AV# [003] 51 OncoVEX GM CSF 51 Dacogen injection 51 PDE4 inhibitor 51 mertansine 51 Lenalidomide 51 seliciclib CYC# 51 KNS # 51 HCD# [002] 51 INCB# [001] 51 cetuximab Erbitux ® 51 phase IIb clinical 51 ACS# 51 TBC# 51 ATL# [002] 51 Imprime PGG 51 BAY #-# 51 Tyrima 51 ARC# [001] 51 Elagolix 51 FOLFOX6 51 orally administered inhibitor 51 nucleoside analog 51 mGluR5 negative 51 IMC A# 51 KX2 51 ARIKACE ™ 51 Symadex 51 bortezomib Velcade ® 51 obatoclax 51 Deadlinepix 51 Phase IIa trials 51 HQK 51 S/GSK# 51 refractory chronic lymphocytic 51 nalbuphine ER 51 Aplidin R 51 intranasal formulation 51 tezampanel 51 nucleoside reverse transcriptase inhibitor 51 epothilone 51 phase IIa 51 mRNA antagonists 51 GRN#L 51 Phase #b/#a 51 MF# [002] 51 LNBs 51 TELINTRA 51 fosbretabulin 51 AV# [001] 51 HCV protease 51 PRX# 51 MAP# 51 HCV protease inhibitor 51 novel prodrug 51 Golimumab 51 GA# [003] 51 favorable tolerability 51 KN# [001] 51 ONTAK 51 generation nucleoside analog 51 selective kinase inhibitor 51 Xanafide 51 antitumor activity 51 CYT# 51 bexarotene 51 Interferon beta 1a 51 PI3K inhibitor 51 Orally administered 51 VELCADE melphalan 51 FOLOTYN ® 51 PI3K/Akt pathway inhibitor 51 KB# [004] 51 CD# CEA 51 corticosteroid dexamethasone 51 PSN# [002] 51 BNC# 50 TG# [003] 50 hypoxia selective 50 Annamycin 50 Pulse Width Modulation PWM 50 histone deacetylase inhibitor 50 phase IIb trial 50 Enkephalin 50 CTAP# Capsules 50 elotuzumab 50 paclitaxel Taxol ® 50 novel synthetic peptide 50 MYDICAR ® 50 Phase 2a Clinical Trial 50 MoxDuo 50 INT# [002] 50 PEGPH# 50 Hsp# Inhibitor 50 Onconase 50 aldehyde dehydrogenase ALDH2 deficiency 50 PrevOnco ™ 50 ALGRX 50 MP# [002] 50 Traficet EN 50 Aurexis 50 GX# [001] 50 BCX# 50 CDK inhibitor 50 APOPTONE 50 administered subcutaneously 50 CA4P 50 GW# [003] 50 diabetic neuropathic pain 50 ADP receptor antagonist 50 investigational humanized monoclonal antibody 50 SERMs 50 docetaxel chemotherapy 50 Bicifadine 50 entinostat 50 Rotigotine 50 E# E# [003] 50 forodesine 50 ISTODAX 50 mapatumumab 50 XMT 50 TNF Tumor Necrosis Factor 50 PD LID 50 Rasagiline 50 imatinib Gleevec ® 50 selective androgen receptor modulator 50 ZD# [001] 50 PS# [001] 50 HGS ETR1 50 HuMax CD4 50 QT# [002] 50 JAK inhibitor 50 GED aPC 50 CYT# potent vascular disrupting 50 Epratuzumab 50 DACH platinum 50 SU# [003] 50 Interferon beta 50 selective agonist 50 alvespimycin 50 ancrod 50 Proxinium TM 50 Erlotinib 50 glufosfamide 50 Hycamtin ® 50 Anticalin R 50 Phase Ib clinical 50 FT# [001] 50 anticancer compound 50 Aeroquin 50 radiation sensitizer 50 ADL# 50 FK# 50 TELCYTA 50 dextromethorphan quinidine 50 Oral NKTR 50 polymerase inhibitor 50 EOquin TM 50 anti leukemic 50 Omacetaxine 50 nucleoside polymerase inhibitor 50 SNT MC# 50 AZD# 50 Preclinical studies suggest 50 urocortin 2 50 Telmisartan 50 Reolysin 50 protein kinase inhibitor 50 SGLT2 inhibitor 50 ORENCIA ® 50 ARC# [002] 50 MB# MB# 50 Cloretazine VNP#M 50 Virtex 5 50 UPLYSO 50 XmAb# 50 ASONEP 49 GRNVAC1 49 Genz # 49 picoPower 49 Safinamide 49 maximally tolerated dose 49 ISIS # 49 PEGylated anti 49 oral ridaforolimus 49 ENMD 49 Seliciclib 49 histone deacetylase HDAC inhibitor 49 dBi gain 49 selective modulator 49 docetaxel Taxotere ® 49 PXD# 49 receptor tyrosine kinase inhibitor 49 VA# [002] 49 UVIDEM 49 Sapacitabine 49 Phase 1b trial 49 pin SOIC package 49 EGS# 49 DirectFET R 49 IFN α 49 bortezomib Velcade 49 VEGFR2 49 multicenter Phase II 49 allosteric modulator NAM 49 Clolar ® 49 levodopa carbidopa 49 mono headset 49 Model #A 49 cannabinor 49 Pertuzumab 49 8 pin MSOP 49 chimeric monoclonal antibody 49 HA# 49 SAR# [004] 49 hyperphenylalaninemia HPA due 49 velafermin 49 Daclizumab 49 Aptivus ® 49 teriflunomide 49 BIO SET 49 perifosine KRX 49 nRF#AP# 49 Phenoptin 49 XL# XL# 49 orally dosed 49 Soliris eculizumab 49 AR# [001] 49 ON #.Na 49 NS# [003] 49 ISL#E [001] 49 Nanobody 49 EOquin 49 huC# DM4 49 STV# 49 Cloretazine 49 thalidomide Thalomid 49 vascular disrupting 49 pegfilgrastim 49 LymphoStat B belimumab 49 R roscovitine 49 CX# [004] 49 Phase 2b clinical trials 49 GAMMAGARD 49 HDAC Inhibitor 49 PKC# 49 alpha#beta# integrin 49 YONDELIS 49 Quinamed 49 ongoing Phase 1b 49 R pioglitazone HCl 49 MEK inhibitors 49 BiTE antibody 49 phase IIa clinical 49 Bendavia 49 RGB # 49 uricase 49 SELZENTRY 49 DIGIMAX 49 humanized monoclonal 49 BC# [003] 49 immune modulatory 49 IPLEX 49 ATryn R 49 GGF2 49 Romidepsin 49 FVIIa 49 JAK inhibitors 49 pioglitazone HCl 49 XP# XP# 49 Locteron 49 sublingual formulation 49 IRX 2 49 sodium glucose cotransporter 49 ProLindac 49 PV# [003] 49 registrational trial 49 HE# [002] 49 melphalan prednisone 49 daclizumab 49 molecularly targeted 49 lapatinib Tykerb 49 Vilazodone 49 novel VDA molecule 49 ganetespib 49 novel anticancer 49 Nanobody ® 49 proteasome inhibitor bortezomib 49 humanized monoclonal antibody 49 candidate CRLX# 49 Anticalin ® 49 OMNARIS 49 pharmacodynamic properties 49 Factor VIIa 49 AKT inhibitor 49 lomitapide 49 Gemcitabine 49 Candesartan 49 telomerase therapeutic 49 Linaclotide 49 PEGylated Fab fragment 49 Impact Wrench 49 entacapone 49 lumiliximab 49 small molecule tyrosine 49 C1 INH 49 TRIOLEX ™ 49 Ixempra 49 boosted protease inhibitor 49 LX# [002] 49 NET# [002] 49 paclitaxel carboplatin 49 CSM# 49 CD# monoclonal antibody 49 humanized anti 49 PI3K/mTOR 49 protein tyrosine phosphatase 1B 49 TLR8 agonist 49 KB# [002] 49 TM# [001] 49 Amrubicin 48 SPC# [001] 48 pertuzumab 48 allogeneic cell 48 davalintide 48 transceiver IC 48 Alocrest 48 Ophena TM 48 highly selective inhibitor 48 MT# [002] 48 Synavive 48 Tarceva TM 48 PLK1 SNALP 48 Actilon 48 L Annamycin 48 ME# [002] 48 etanercept Enbrel 48 Phase Ib 48 sodium thiosulfate STS 48 oxidative stress inducer 48 sunitinib malate 48 THR beta agonist 48 bazedoxifene selective estrogen receptor 48 CEQ# 48 TQFN package 48 novel histone deacetylase 48 Virulizin ® 48 MabCampath 48 cutaneous T cell 48 eniluracil 48 Enzastaurin 48 Zybrestat 48 1RU rack 48 trodusquemine 48 Elotuzumab 48 gamma secretase inhibitor 48 GLYX 48 trastuzumab DM1 T DM1 48 SRT# [003] 48 ProSavin 48 Perifosine 48 TLK# 48 Panzem 48 ELND-#/AZD-# 48 Phase 2b 48 ocular formulation 48 multitargeted 48 BAL# [002] 48 monotherapy 48 C# C# [003] 48 Fulvestrant 48 HCV protease inhibitors 48 solithromycin 48 aurora kinase 48 paclitaxel Taxol 48 Dalbavancin 48 CB# [002] 48 PDX pralatrexate 48 Hsp# inhibition 48 NN# [001] 48 leukemia AML 48 selective antagonist 48 CORT # 48 Chemophase 48 Sony Motionflow 48 Trastuzumab 48 decitabine 48 sargramostim 48 GLPG# 48 Ofatumumab 48 combinability 48 Nav#.# 48 Pimavanserin 48 CBLC# 48 Aurora Kinase 48 AZT zidovudine Retrovir 48 Taxotere ® 48 TAFA# 48 #ES [002] 48 Angiotensin Converting Enzyme 48 XYOTAX TM 48 androgen independent 48 LymphoStat B TM 48 IMA# 48 NP2 Enkephalin 48 BRAF inhibitor 48 ORENCIA R 48 octreotide acetate 48 NFkB 48 Nexavar sorafenib 48 pralatrexate 48 JAK1 48 ALVESCO R 48 tumor necrosis 48 2 methoxyestradiol 48 NEUGENE 48 Virulizin R 48 Phase 1b clinical 48 RS#/# 48 ® pioglitazone HCl 48 danoprevir 48 dasatinib Sprycel ® 48 Aflibercept 48 PLX# 48 detachable antenna 48 Keppra XR 48 proprietary polysaccharide 48 EGFR HER2 48 PNP inhibitor 48 XL# anticancer compounds 48 Civacir 48 ulimorelin 48 mu opioid receptor antagonist 48 immunotherapeutic agent 48 DIN rail mounted 48 proteasome inhibitor 48 Exemestane 48 rhIL 7 48 peripherally acting 48 ESBA# 48 potent inhibitor 48 Vaprisol 48 STM# [002] 48 lupus nephritis 48 phase IIb 48 GALNS 48 MAGE A3 ASCI 48 Ceflatonin R 48 brivaracetam 48 evaluating satraplatin 48 virus HCV protease inhibitor 48 humanized antibody 48 Azedra 48 insulin sensitizer 48 ApoB SNALP 48 Gemzar ® 48 palonosetron 48 elvitegravir 48 inhaled formulation 48 highly selective endothelin 48 SLx 48 IAP inhibitor 48 TASQ 48 PF# [002] 48 Cloretazine ® 48 trabectedin 48 otelixizumab 48 veltuzumab 48 IMC #B 48 baminercept 48 selective estrogen receptor 48 MNTX 48 Phase IIIb clinical 48 teduglutide 48 TRX1 48 trastuzumab emtansine T DM1 48 L BLP# 48 AZX# 48 Ocrelizumab 48 MBX 48 OncoVEX 48 Marqibo TM 48 Zoraxel TM 48 Eizo FlexScan 48 cathepsin K inhibitor 48 investigational pan BCR 48 vandetanib 47 PEG PAL 47 GL# [003] 47 BrachySil TM 47 Xeloda ® 47 6R BH4 47 BXT # 47 Anticalin 47 NV# [001] 47 farletuzumab 47 elesclomol 47 insulin sensitizing 47 DV# [001] 47 HuLuc# 47 immunofluorescence staining 47 idarubicin 47 GRN# 47 sd rxRNA 47 angiotensin receptor blocker ARB 47 aripiprazole Abilify 47 Mipomersen 47 investigational immunotherapy 47 Revascor TM 47 Dapagliflozin 47 Genasense ® oblimersen 47 RANK ligand 47 coupled inductor 47 anticancer agent 47 enzastaurin 47 preclinical efficacy 47 lintuzumab SGN 47 BelaSigna 47 SU# [002] 47 Phase IIb clinical trials 47 AQ4N 47 JAK#/JAK# 47 6mm x 6mm 47 RG# [001] 47 ALS #-# 47 TRO# 47 platinum chemotherapeutic 47 mGluR2 NAM 47 relapsed multiple myeloma 47 anti angiogenic agent 47 Eltrombopag 47 reversible inhibitor 47 XP# [003] 47 5 HT2C receptor 47 bendamustine 47 Sorafenib 47 Methylnaltrexone 47 AEG# 47 CR# vcMMAE 47 CIMZIA TM 47 Huntexil 47 CD# antibody [001] 47 ELND# 47 Lubiprostone 47 partial agonist 47 SP#E 47 ZK EPO 47 pharmacodynamic PD 47 dose limiting toxicities 47 axitinib 47 antiangiogenic activity 47 MEK inhibitor RDEA# 47 ELACYT 47 Phase 2b clinical 47 RLY# 47 MoxDuo ® IR 47 MAXY alpha 47 IWLAN 47 immunomodulatory therapy 47 PI3 Kinase 47 JAK2 inhibitor 47 IV bolus formulation 47 mitogen activated ERK kinase 47 Cimzia TM 47 EX# [002] 47 relapsed refractory multiple myeloma 47 Bortezomib 47 targeting CD# 47 seliciclib 47 Phase IIb clinical 47 Tezampanel 47 Rituximab 47 Eculizumab 47 Thiarabine 47 OptoCooler HV# 47 Phase 2a 47 SL# [004] 47 HspE7 47 OvaRex ® MAb 47 Ampakine 47 Durezol 47 inhibitor PPI 47 Vidaza azacitidine 47 BrachySil 47 VAPRISOL 47 fluticasone furoate 47 basal insulin 47 refractory AML 47 PAM# [002] 47 SFP transceivers 47 pharmacokinetic PK profile 47 potent inhibition 47 PET# 47 NEC NP# 47 Vicriviroc 47 XOPENEX HFA 47 siRNA mediated 47 eZdsp 47 vascular disrupting agents 47 reslizumab 47 Axona 47 low dose cytarabine 47 adipiplon 47 mitomycin 47 Vidaza ® 47 Phase 1a clinical 47 PMBus compliant 47 pharmacokinetic profile 47 MIC#/# 47 demonstrated antitumor activity 47 SCH # 47 LHRH antagonists 47 investigational compound 47 cetuximab Erbitux R 47 glucagon receptor 47 XC Cube 47 Phase Ib clinical trials 47 rilonacept 47 regulator CFTR protein 47 7 x 7mm 47 tivozanib 47 renin inhibitors 47 XENPAK 47 PCK# 47 CCX# B 47 CRLX# 47 tezampanel NGX# 47 methionine aminopeptidase 47 TORISEL 47 Tolvaptan 47 Uvidem 47 multi kinase inhibitor 47 cMET 47 valopicitabine 47 OvaRex R 47 Coversyl 47 Afatinib 47 Carfilzomib 47 tanespimycin 47 BF# [003] 47 LEUKINE 47 Hedgehog Pathway Inhibitor 47 pharmacodynamic 47 lamivudine zidovudine 47 FlexTT5 47 UsiRNAs 47 Hsp# inhibitors 47 BEMA TM Fentanyl 47 UltraAV 47 ara C 47 OMP #M# 47 BiTE 47 QSFP 47 Solazed TM 47 vivo efficacy 47 cilengitide 47 ALN TTR# 47 potent antitumor activity 47 SARMs 47 CX# [002] 47 LentiVector technology 47 Fludara 47 IronPoint Mobility 47 opioid induced bowel dysfunction 47 Naproxcinod 47 Sitrans 47 Nasulin 47 antiviral activity 47 Abbokinase 47 cortisol synthesis 47 hypoxia activated prodrug 46 polymerase inhibitors 46 asynchronous motors 46 Zerenex 46 CCX# 46 #us [002] 46 DNA intercalator 46 Phase 2a trial 46 Valsartan 46 DE# [001] 46 VEGF Trap 46 crizotinib PF # 46 ErbB3 HER3 46 #beta HSD1 46 Revlimid lenalidomide 46 APD# 46 nonclinical studies 46 Fx #A 46 BLA filing 46 ozarelix 46 HER3 46 Viramidine 46 #/#Base-T 46 TRX4 46 multiple myeloma MM 46 chemically modified siRNA 46 amylin 46 Panasonic KX 46 MyVax R 46 Vidofludimus 46 Darunavir 46 Biolimus A9 46 thymalfasin 46 lorvotuzumab mertansine 46 ofatumumab 46 telomerase inhibitor drug 46 eltrombopag 46 Chrysalin 46 AVE# 46 Romiplostim 46 CLORETAZINE TM VNP#M 46 adalimumab Humira 46 synthetic retinoid 46 AOZ# 46 AACR NCI EORTC 46 Phase #/#a trial 46 galiximab 46 Solazed 46 R8C/Tiny 46 AP# [003] 46 Cloretazine R 46 SiriusConnect 46 adecatumumab 46 PRX # 46 Bavituximab 46 Talabostat 46 huN# DM1 46 MT# MEDI 46 5 HT3 receptor 46 ZYBRESTAT 46 MET RET 46 receptor agonist 46 Vicinium TM 46 samalizumab 46 JVC GR 46 Phase 2b study 46 recurrent glioblastoma 46 MAXY G# 46 AX# [001] 46 Novel Oral 46 Boceprevir 46 IND enabling 46 #x#G [002] 46 dose cohort 46 Phase 2b trial 46 albiglutide 46 Survivin antagonist 46 RDEA# 46 Tarvacin 46 Entereg R 46 BENLYSTA ® 46 posaconazole 46 detachable faceplate 46 GM# [003] 46 triband GSM 46 Phase IIa trial 46 PDGFR 46 mTOR inhibitors 46 CTA# Injection 46 IAP inhibitors 46 echinocandin 46 PrevOnco 46 omacetaxine 46 Neulasta ® 46 Polymer Microspheres 46 ALK inhibitor 46 LNP formulations 46 Resten NG 46 IMiDs 46 muscarinic 46 Initiate Phase 46 RGBHV 46 romidepsin 46 Dabigatran etexilate 46 Ganciclovir 46 pharmacokinetic PK study 46 #HD [002] 46 xanthine oxidase inhibitor 46 dihydrochloride 46 S#T [001] 46 non porcine pancreatic 46 REG1 46 AVN# [001] 46 RJ# connector 46 pomalidomide 46 Phase IIb 46 TYKERB 46 MGCD# [002] 46 systemically administered 46 Tanespimycin 46 DV# [002] 46 calcineurin inhibitors 46 #W# [007] 46 Procoralan 46 Avago ACPL 46 IMGN# 46 eculizumab 46 plus gemcitabine 46 C#S 46 VSX #TXH 46 pegylated liposomal doxorubicin 46 nab paclitaxel 46 opioid receptor antagonist 46 PRISTIQ 46 Stedivaze 46 AEGR 46 Elvitegravir 46 sorafenib Nexavar ® 46 Tarceva erlotinib 46 drug conjugate 46 TREANDA 46 5 HT3 antagonist 46 Carvedilol 46 randomized controlled Phase 46 alagebrium 46 Microplasmin 46 rFVIIIFc 46 dyskinesia PD LID 46 Tarvacin TM 46 GAP #B# 46 rNAPc2 46 PEG Interferon lambda 46 5 HT2A receptor 46 investigational oral 46 ALN RSV# 46 metastatic CRC 46 drug eluting coronary stent 46 measures #x#x#mm [004] 46 metastatic renal cell carcinoma 46 GSK# [001] 46 visilizumab 46 Phase IIB 46 Harmon Kardon speakers 46 BZL# 46 INCB# [003] 46 randomized discontinuation trial 46 nucleoside analogues 46 TLR7 46 ANA# 46 Ostarine 46 CoFactor 46 Multimedia Projectors 46 blinded randomized placebo controlled 46 Satraplatin 46 Azacitidine 46 talabostat 46 cediranib 46 serine protease 46 Amplimexon 46 Phase Ib II 46 AZILECT R 46 metastatic hormone refractory 46 Revimmune 46 registrational 46 Antiviral Activity 46 Alpharadin 46 ALN TTR 46 ZOLINZA 46 Bosentan 46 Phase 2a Study 46 serotonin norepinephrine reuptake inhibitor 46 M2 subunit 46 VEGFR2 inhibitor 46 Temsirolimus 46 CCR2 46 XFP transceivers 46 anti amnesic 46 leading oral taxane 46 potent topoisomerase II 46 satraplatin Phase 46 HuMax CD# 45 Proellex TM 45 Cethrin 45 insulin sensitizers 45 NVA# 45 EFOY Pro Series 45 Guanilib 45 investigational integrase inhibitor 45 darinaparsin 45 confirmatory Phase III 45 receptor modulators 45 MOZOBIL 45 LEICA D 45 MG# [003] 45 Ambrisentan 45 Bruton tyrosine kinase Btk 45 gastrin 45 Abacavir 45 bicifadine 45 Phase IIb trials